Certified by Founder
Lodge
Vima Therapeutics
start up
United States
- Cambridge, Massachusetts
- 30/05/2025
- Series A
- $60,000,000
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders.
We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease.
Vima brings together a team of physicians, scientists, and drug developers with deep expertise in movement disorders and a shared commitment to deliver a meaningful oral therapy for patients.
- Industry Biotechnology Research
- Website https://vimatx.com/
- LinkedIn https://www.linkedin.com/company/vima-therapeutics/
Clairity, Inc. | $43,000,000 | (Nov 14, 2025)
CoRun.ai | $3,500,000 | (Nov 14, 2025)
Park Loyalty | Undisclosed Amount | (Nov 14, 2025)
Carbon(US) | $60,000,000 | (Nov 14, 2025)
Big Rentals | $2,800,000 | (Nov 14, 2025)
Bindwell | $6,000,000 | (Nov 14, 2025)
Anzen Insurance | $16,000,000 | (Nov 14, 2025)
Beacon Biosignals | $86,000,000 | (Nov 14, 2025)
Fabric8Labs | $50,000,000 | (Nov 14, 2025)
Songscription | $5,000,000 | (Nov 14, 2025)
sunday (US) | $21,000,000 | (Nov 14, 2025)
Maybern | $50,000,000 | (Nov 14, 2025)